Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Bendamustine + Rituximab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Bendamustine Treanda Ribomustin|SyB L-0501|SDX-105 Chemotherapy - Alkylating 14 Treanda (bendamustine) is an alkylating agent with unique mechanisms, resulting in increased DNA damage and base-excision DNA repair pathway induction, and potentially leading to decreased growth of tumors, including those resistant to other alkylating agents (PMID: 18172283, PMID: 19117340, PMID: 19224851). Treanda (bendamustine) is FDA approved for use in chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma (FDA.gov).
Rituximab Rituxan IDEC-C2B8|MabThera CD20 Antibody 10 Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown mantle cell lymphoma not applicable Bendamustine + Rituximab Phase III Actionable In a Phase III trial, Rituximab and Bendamustine combination therapy resulted in improved 5-year progression free survival rate (66.5% vs 55.8%), but no difference in overall survival rate (81.7% vs 85%) compared to R-CHOP/R-CVP regimen in patients with indolent non-Hodgkin lymphoma or mantle cell lymphoma (J Clin Oncol 35, 2017 (suppl; abstr 7500)). detail...
Unknown unknown non-Hodgkin lymphoma not applicable Bendamustine + Rituximab Phase III Actionable In a Phase III trial, Rituximab and Bendamustine combination therapy resulted in improved 5-year progression free survival rate (66.5% vs 55.8%), but no difference in overall survival rate (81.7% vs 85%) compared to R-CHOP/R-CVP regimen in patients with indolent non-Hodgkin lymphoma or mantle cell lymphoma (J Clin Oncol 35, 2017 (suppl; abstr 7500)). detail...

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT02257567 Phase Ib/II Bendamustine + Rituximab Polatuzumab vedotin-piiq Obinutuzumab A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT03336333 Phase III Zanubrutinib Bendamustine + Rituximab A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL Recruiting
NCT01059786 Phase II Bendamustine + Rituximab Pentostatin + Rituximab Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Recruiting
NCT02187861 Phase II Bendamustine + Rituximab Bendamustine + Rituximab + Venetoclax Rituximab + Venetoclax A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma Completed
NCT02626455 Phase III Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting
NCT03609593 Phase II Rituximab Bendamustine + Rituximab Venetoclax Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia Recruiting
NCT01216683 Phase II Bendamustine + Rituximab Bortezomib Lenalidomide Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Active, not recruiting
NCT02763319 Phase II Bendamustine + Tafasitamab-cxix Bendamustine + Rituximab A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND) Recruiting
NCT03836261 Phase III Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL Recruiting
NCT02972840 Phase III Bendamustine + Rituximab Acalabrutinib + Bendamustine + Rituximab A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma Recruiting
NCT02576275 Phase III Bendamustine + Rituximab Duvelisib A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Withdrawn
NCT01732926 Phase III Idelalisib Bendamustine + Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated
NCT04002297 Phase III Rituximab + Zanubrutinib Bendamustine + Rituximab Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Patients With Untreated Mantle Cell Lymphoma Recruiting
NCT01974440 Phase III Ibrutinib Bendamustine + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Active, not recruiting
NCT04285567 Phase III Obinutuzumab + Venetoclax Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO) Recruiting
NCT02951156 Phase III Avelumab + Azacitidine + Utomilumab Avelumab + Rituximab + Utomilumab Bendamustine + Rituximab Gemcitabine + Oxaliplatin + Rituximab Avelumab + Bendamustine + Rituximab Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Completed


Additional content available in CKB BOOST